Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 3, 2007 - Issue 2
Submit an article Journal homepage
114
Views
14
CrossRef citations to date
0
Altmetric
Review

Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs

Michael Murray University of Sydney, Pharmacogenomics and Drug Development Group, Faculty of Pharmacy, NSW 2006, Australia. [email protected]
Pages 185-196 | Published online: 11 Apr 2007

Bibliography

  • WIWI CA, WAXMAN DJ: Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors (2004) 22(2):79-88.
  • DHIR RN, DWORAKOWSKI W, THANGAVEL C, SHAPIRO BH: Sexually dimorphic regulation of hepatic isoforms of human cytochrome P450 by growth hormone. J. Pharmacol. Exp. Ther. (2006) 316(1):87-94.
  • MODE A, WIERSMA-LARSSON E, STROM A, ZAPHIROPOULOS PG, GUSTAFSSON JA: A dual role of growth hormone as a feminizing and masculinizing factor in the control of sex-specific cytochrome P450 isozymes in rat liver. J. Endocrinol. (1989) 120(2):311-317.
  • TANNENBAUM GS, CHOI HK, GURD W, WAXMAN DJ: Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. Endocrinology (2001) 142(11):4599-4606.
  • GUSTAFSSON JA, MODE A, NORSTEDT G, SKETT P: Sex steroid induced changes in hepatic enzymes. Ann. Rev. Physiol. (1983) 45:51-60.
  • FROHMAN LA, DOWNS TR, CHOMCZYNSKI P: Regulation of growth hormone secretion. Frontiers Neuroendocrinol. (1992) 13(4):344-405.
  • GEBERT CA, PARK SH, WAXMAN DJ: Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Mol. Endocrinol. (1997) 11(4):400-414.
  • SCHINDLER C, DARNELL JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann. Rev. Biochem. (1995) 64:621-651.
  • SHUAI K: The STAT family of proteins in cytokine signaling. Prog. Biophys. Mol. Biol. (1999) 71(3-4):405-422.
  • RAM PA, PARK SH, CHOI HK, WAXMAN DJ: Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. J. Biol. Chem. (1996) 271(10):5929-5940.
  • PARK SH, YAMASHITA H, RUI H, WAXMAN DJ: Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity. Mol. Endocrinol. (2001) 15(12):2157-2171.
  • RAM PA, WAXMAN DJ: Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J. Biol. Chem. (1997) 272(28):17694-17702.
  • YU CL, JIN YJ, BURAKOFF SJ: Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J. Biol. Chem. (2000) 275(1):599-604.
  • SHUAI K, LIU B: Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. (2003) 3(11):900-911.
  • MATSUMOTO A, MASUHARA M, MITSUI K et al.: CIS, a cytokine-inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood (1997) 89(9):3148-3154.
  • TOMIC S, CHUGHTAI N, ALI S: SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor. Mol. Cell. Endocrinol. (1999) 158(1-2):45-54.
  • SUNDSETH SS, WAXMAN DJ: Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid ω-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. J. Biol. Chem. (1992) 267(6):3915-3921.
  • WAXMAN DJ, RAM PA, PAMPORI NA, SHAPIRO BH: Growth hormone regulation of male-specific rat liver P450s 2A2 and 3A2: induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate. Mol. Pharmacol. (1995) 48(5):790-797.
  • HAUSWIRTH JW, BRIZUELA BS: The differential effects of chemical carcinogens on vitamin A status and on microsomal drug metabolism in normal and vitamin A-deficient rats. Cancer Res. (1976) 36(6):1941-1946.
  • MARTINI R, BUTLER AM, JIANG XM, MURRAY M: Pretranslational down regulation of cytochrome P450 2C11 in vitamin A-deficient male rat liver: prevention by dietary inclusion of retinoic acid. J. Pharmacol. Exp. Ther. (1995) 273(1):427-434.
  • CORREIA MA: Human and rat liver cytochromes P450: Functional markers, diagnostic inhibitor probes, and parameters frequently used in P450 studies. In: Cytochrome P450 Structure, Mechanism, and Biochemistry (3rd edition). Ortiz de Montellano PR (Ed.), Kluwer Academic/Plenum Publishers, New York, USA (2005):619-657.
  • GUENGERICH FP, DANNAN GA, WRIGHT ST, MARTIN MV, KAMINSKY LS: Purification and characterization of liver microsomal cytochromes P450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone. Biochemistry (1982) 21(23):6019-6030.
  • RYAN DE, LEVIN W: Purification and characterization of hepatic microsomal cytochrome P450. Pharmacol. Ther. (1990) 45(2):153-239.
  • MURRAY M, BUTLER AM, FIALA-BEER E, SU GM: Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. FEBS Lett. (2005) 205(17):3669-3673.
  • MURRAY M, BUTLER AM, AGUS C: Restoration of cytochrome P450 2C11 in vitamin A-deficient rat liver by exogenous androgen. FASEB J. (1996) 10(9):1058-1063.
  • MURRAY M, SEFTON RM, CROFT KD, BUTLER AM: Differential regulation of endobiotic-oxidizing cytochromes P450 in vitamin A-deficient male rat liver. Br. J. Pharmacol. (2001) 134(7):1487-1497.
  • BREEN JJ, MATSUURA T, ROSS AC, GURR JA: Regulation of thyroid-stimulating hormone β-subunit and growth hormone messenger ribonucleic acid levels in the rat: effect of vitamin A status. Endocrinology (1995) 136(2):543-549.
  • MALLO F, LAMAS JA, CASANUEVA FF, DIEGUEZ C: Effect of retinoic acid deficiency on in vivo and in vitro GH responses to GHRH in male rats. Neuroendocrinology (1992) 55(6):642-647.
  • WESTIN S, SONNEVELD E, VAN DER LEEDE BM, VAN DER SAAG PT, GUSTAFSSON JÅ, MODE A: CYP2C7 expression in rat liver and hepatocytes: regulation by retinoids. Mol. Cell. Endocrinol. (1997) 129(2):169-179.
  • LOMBARDI B, PANI P, SCHLUNK FF: Choline-deficiency fatty liver: impaired release of hepatic triglycerides. J. Lipid Res. (1968) 9(4):437-446.
  • MURRAY M, ZALUZNY L, DANNAN GA, GUENGERICH FP, FARRELL GC: Altered regulation of cytochrome P450 enzymes in choline-deficient cirrhotic male rat liver: impaired regulation and activity of the male-specific androst-4-ene-3,17-dione 16α-hydroxylase, cytochrome P450UT-A, in hepatic cirrhosis. Mol. Pharmacol. (1987) 31(1):117-121.
  • MURRAY M, CANTRILL E, MEHTA I, FARRELL GC: Impaired expression of microsomal cytochrome P450 2C11 in choline-deficient rat liver during the development of cirrhosis. J. Pharmacol. Exp. Ther. (1992) 261(1):373-380.
  • SABESIN SM, FRASE S, RAGLAND JB: Accumulation of nascent lipoproteins in rat hepatic golgi during induction of fatty liver by orotic acid. Lab. Invest. (1977) 37(2):127-135.
  • SU GM, SEFTON RM, MURRAY M: Down-regulation of rat hepatic microsomal cytochromes P450 in microvesicular steatosis induced by orotic acid. J. Pharmacol. Exp. Ther. (1999) 291(3):953-959.
  • LING PR, SMITH RJ, KIE S, BOYCE P, BISTRIAN BR: Effects of protein malnutrition on IL-6-mediated signaling in the liver and the systemic acute-phase response in rats. Am. J. Physiol. Regulat. Integr. Comp. Physiol. (2004) 287(4):R801-R808.
  • KELLEY GL, ALLAN G, AZHAR S: High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology (2004) 145(2):548-555.
  • WEI Y, WANG D, PAGLIASSOTTI MJ: Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. J. Nutr. (2005) 135(7):1642-1646.
  • WALSH MJ, JONSSON JR, RICHARDSON MM et al.: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut (2006) 55(4):529-535.
  • LEE KAW: Dimeric transcription factor families: it takes two to tango but who decides on partners and the venue? J. Cell Sci. (1992) 103(1):9-14.
  • MARDEN NY, FIALA-BEER E, XIANG SH, MURRAY M: Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochem. J. (2003) 373(3):669-680.
  • MARDEN NY, MURRAY M: Characterization of a c-Jun-responsive module in the 5′-flank of the human CYP2J2 gene that regulates transactivation. Biochem. J. (2005) 391(3):631-640.
  • KWAK MK, WAKABAYASHI N, ITOH K, MOTOHASHI H, YAMAMOTO M, KENSLER TW: Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. (2003) 278:8135-8145.
  • FLACHS P, HORAKOVA O, BRAUNER P et al.: Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce β-oxidation in white fat. Diabetologia (2005) 48(11):2365-2375.
  • EVANS RM: The steroid and thyroid hormone receptor superfamily. Science (1988) 240(4854):889-895.
  • GLASS CK, ROSENFELD MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. (2000) 14(2):121-141.
  • MCKENNA NJ, O’MALLEY BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell (2002) 108(4):465-474.
  • YANAGISAWA J, KITAGAWA H, YANAGIDA M et al.: Nuclear receptor function requires a TFTC-type histone acetyl transferase complex. Mol. Cell (2002) 9(3):553-562.
  • MOORE JT, GOODWIN B, WILLSON TM, KLIEWER SA: Nuclear receptor regulation of genes involved in bile acid metabolism. Crit. Rev. Eukaryot. Gene Expr. (2002) 12(2):119-135.
  • WATKINS RE, NOBLE SM, REDINBO MR: Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Disc. Develop. (2002) 5(1):150-158.
  • GLASS CK: Differential recognition of target genes by nuclear receptor monomers, dimers and heterodimers. Endocr. Rev. (1994) 15(3):1503-1519.
  • SPIEGELMAN BM, HEINRICH R: Biological control through regulated transcriptional coactivators. Cell (2004) 119(2):157-167.
  • SLADEK FM, ZHONG WM, LAI E, DARNELL JE Jr: Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. (1990) 4(12B):2353-2365.
  • WISELY GB, MILLER AB, DAVIS RG et al.: Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure (2002) 10(9):1225-1234.
  • DHE-PAGANON S, DUDA K, IWAMOTO M, CHI YI, SHOELSON SE: Crystal structure of the HNF4α ligand binding domain in complex with endogenous fatty acid ligand. J. Biol. Chem. (2002) 277(41):37973-37976.
  • CHEN D, LEPAR G, KEMPER B: A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4. J. Biol. Chem. (1994) 269(7):5420-5427.
  • CAIRNS W, SMITH CA, MCLAREN AW, WOLF CR: Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J. Biol. Chem. (1996) 271(41):25269-25276.
  • CORCHERO J, GRANVIL CP, AKIYAMA TE et al.: The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol. Pharmacol. (2001) 60(6):1260-1267.
  • JOVER R, BORT R, GOMEZ-LECHON MJ, CASTELL JV: Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology (2001) 33(3):668-675.
  • TIRONA RG, LEE W, LEAKE BF et al.: The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med. (2003) 9(2):220-224.
  • WIWI CA, GUPTE M, WAXMAN DJ: Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4α-deficient mice. Mol. Endocrinol. (2004) 18(8):1975-1987.
  • OGINO M, NAGATA K, MIYATA M, YAMAZOE Y: Hepatocyte nuclear factor 4-mediated activation of rat CYP3A1 gene and its modes of modulation by apolipoprotein AI regulatory protein I and v-ErbA-related protein 3. Arch. Biochem. Biophys. (1999) 362(1):32-37.
  • NAKAYAMA K, SUDO Y, SASAKI Y, IWATA H, TAKAHASHI M, KAMATAKI T: Studies on transcriptional regulation of Cyp3a16 gene in mouse livers by application of direct DNA injection method. Biochem. Biophys. Res. Commun. (2001) 287(4):820-824.
  • JOHNSON EF, HSU MH, SAVAS U, GRIFFIN KJ: Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology (2002) 181-182:203-206.
  • IP E, FARRELL GC, ROBERTSON G, HALL P, KIRSCH R, LECLERCQ I: Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology (2003) 38(1):123-132.
  • SU GM, FIALA-BEER E, WEBER J, JAHN D, ROBERTSON GR, MURRAY M: Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochem. Pharmacol. (2005) 69(4):709-717.
  • PALMER CN, HSU MH, GRIFFIN KJ, RAUCY JL, JOHNSON EF: Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. (1998) 53(1):14-22.
  • LAWRENCE JW, LI Y, CHEN S et al.: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)-α. PPAR-α fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J. Biol. Chem. (2001) 276(34):31521-31527.
  • GLASS CK: Going nuclear in metabolic and cardiovascular disease. J. Clin. Invest. (2006) 116(3):556-560.
  • TONTONOZ P, MANGELSDORF DJ: Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. (2003) 17(6):985-993.
  • MURRAY M, CANTRILL E, MARTINI R, FARRELL GC: Increased expression of cytochrome P450 IIIA2 in male rat liver after dietary vitamin A supplementation. Arch. Biochem. Biophys. (1991) 286(2):618-624.
  • RUHL R: Induction of PXR-mediated metabolism by β-carotene. Biochim. Biophys. Acta (2005) 1740(2):162-169.
  • WESTIN S, MODE A, MURRAY M, CHEN R, GUSTAFSSON JÅ: Growth hormone and vitamin A induce P4502C7 mRNA expression in primary rat hepatocytes. Mol. Pharmacol. (1993) 44(5):997-1002.
  • WANG Y, ZOLFAGHARI R, ROSS AC: Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo. Arch. Biochem. Biophys. (2002) 401(2):235-243.
  • ROSS AC: Retinoid production and catabolism: role of diet in regulating retinol esterification and retinoic acid oxidation. J. Nutr. (2003) 133(1):291S-296S.
  • LOUDIG O, BABICHUK C, WHITE J, ABU-ABED S, MUELLER C, PETKOVIC M: Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism. Mol. Endocrinol. (2000) 14(9):1483-1497.
  • YAMAMOTO Y, ZOLFAGHARI R, ROSS AC: Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats. FASEB J. (2000) 14(13):2119-2127.
  • KATO S, MANO H, KUMAZAWA T, YOSHIZAWA Y, KOJIMA R, MASUSHIGE S: Effect of retinoid status on α, β and γ retinoic acid receptor mRNA levels in various rat tissues. Biochem. J. (1992) 286(3):755-760.
  • ZOLFAGHARI R, ROSS AC: Chronic vitamin A intake affects the expression of mRNA for apolipoprotein A-I, but not for nuclear retinoid receptors, in liver of young and aging Lewis rats. Arch. Biochem. Biophys. (1995) 323(2):258-264.
  • WILLIAMS DE, CARPENTER HM, BUHLER DR, KELLY JD, DUTCHUK M: Alterations in lipid peroxidation, antioxidant enzymes, and carcinogen metabolism in liver microsomes of vitamin E-deficient trout and rat. Toxicol. Appl. Pharmacol. (1992) 116(1):78-84.
  • MURRAY M: In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver. Biochem. Pharmacol. (1991) 42(11):2107-2114.
  • LANDES N, PFLUGER P, KLUTH D et al.: Vitamin E activates gene expression via the pregnane X receptor. Biochem. Pharmacol. (2003) 65(2):269-273.
  • BRIGELIUS-FLOHE R: Vitamin E and drug metabolism. Biochem. Biophys. Res. Commun. (2003) 305(3):737-740.
  • KLUTH D, LANDES N, PFLUGER P et al.: Modulation of Cyp3a11 mRNA expression by α-tocopherol but not γ-tocotrienol in mice. Free Rad. Biol. Med. (2005) 38(4):507-514.
  • RUSSELL DW, SETCHELL KD: Bile acid biosynthesis. Biochemistry (1992) 31(20):4737-4749.
  • PEET DJ, TURLEY SD, MA W et al.: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell (1998) 93(5):693-704.
  • CHIANG JY, KIMMEL R, WEINBERGER C, STROUP D: Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. (2000) 275(15):10918-10924.
  • GOODWIN B, GAUTHIER KC, UMETANI M et al.: Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. USA (2003) 100(1):223-228.
  • GU YZ, HOGENESCH JB, BRADFIELD CA: The PAS superfamily: sensors of environmental and developmental signals. Ann. Rev. Pharmacol. Toxicol. (2000) 40:519-561.
  • POLAND A, GLOVER E, KENDE AS: Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. (1976) 251(16):4936-4946.
  • BACKLUND M, JOHANSSON I, MKRTCHIAN S, INGELMAN-SUNDBERG M: Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. J. Biol. Chem. (1997) 272(50):31755-31763.
  • BACKLUND M, INGELMAN-SUNDBERG M: Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell. Signal. (2005) 17(1):39-48.
  • KIKUCHI H, HOSSAIN A: Signal transduction-mediated CYP1A1 induction by omeprazole in human HepG2 cells. Exp. Toxicol. Pathol. (1999) 51(4-5):342-346.
  • GRADELET S, ASTORG P, LECLERC J, CHEVALIER J, VERNEVAUT MF, SIESS MH: Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobiotica (1996) 26(1):49-63.
  • GAMBONE CJ, HUTCHESON JM, GABRIEL JL et al.: Unique property of some synthetic retinoids: activation of the aryl hydrocarbon receptor pathway. Mol. Pharmacol. (2002) 61(2):334-342.
  • GIBSON GG, PHILLIPS A, AOUABDI S, PLANT K, PLANT N: Transcriptional regulation of the human pregnane-X receptor. Drug Metab. Rev. (2006) 38(1-2):31-49.
  • MAGLICH JM, STOLTZ CM, GOODWIN B, HAWKINS-BROWN D, MOORE JT, KLIEWER SA: Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. (2002) 62(3):638-646.
  • VIDAL M, RAMANA CV, DUSSO AS: Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol. Cell. Biol. (2002) 22(8):2777-2787.
  • LECHNER J, WELTE T, TOMASI JK et al.: Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of β-casein gene transcription. J. Biol. Chem. (1997) 272(33):20954-20960.
  • GRONER B, FRITSCHE M, STOCKLIN E et al.: Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. Growth Hormone IGF Res. (2000) 10(Suppl. B):S15-S20.
  • STEWART WC, MORRISON RF, YOUNG SL, STEPHENS JM: Regulation of signal transducers and activators of transcription (STATs) by effectors of adipogenesis: coordinate regulation of STATs 1, 5A, and 5B with peroxisome proliferator-activated receptor-γ and C/AAAT enhancer binding protein-α. Biochim. Biophys. Acta (1999) 1452(2):188-196.
  • ZHOU YC, WAXMAN DJ: STAT5b down-regulates peroxisome proliferator-activated receptor-α transcription by inhibition of ligand-independent activation function region-1 trans-activation domain. J. Biol. Chem. (1999) 274(42):29874-29882.
  • SHIPLEY JM, WAXMAN DJ: Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ. Mol. Pharmacol. (2003) 64(2):355-364.
  • BORNHEIM LM, CORREIA MA: Selective inactivation of mouse liver cytochrome P450IIIA by cannabidiol. Mol. Pharmacol. (1990) 38(3):319-326.
  • KISTLER A, LIECHTI H, PICHARD L et al.: Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch. Toxicol. (2002) 75(11-12):665-675.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.